iBio (IBIO)
(Delayed Data from AMEX)
$1.99 USD
-0.04 (-1.97%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.97 -0.02 (-1.01%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for iBio, Inc falls in the month of June .
All items in Millions except EPS data.
6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 | |
---|---|---|---|---|---|
Sales | 0 | 2 | 2 | 2 | 2 |
Cost Of Goods | 0 | 0 | 1 | 0 | 0 |
Gross Profit | 0 | 2 | 1 | 2 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 29 | 52 | 32 | 16 | 18 |
Income After Depreciation & Amortization | -29 | -50 | -31 | -14 | -16 |
Non-Operating Income | 0 | 1 | 10 | 0 | 0 |
Interest Expense | 0 | 1 | 2 | 2 | 2 |
Pretax Income | -29 | -50 | -23 | -16 | -18 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -29 | -50 | -23 | -16 | -18 |
Extras & Discontinued Operations | -36 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -65 | -50 | -23 | -16 | -18 |
Depreciation Footnote | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -28 | -45 | -28 | -12 | -14 |
Depreciation & Amortization (Cash Flow) | 2 | 4 | 3 | 2 | 2 |
Income After Depreciation & Amortization | -29 | -50 | -31 | -14 | -16 |
Earnings Per Share Data | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Average Shares | 0.61 | 0.44 | 0.39 | 0.13 | NA |
Diluted EPS Before Non-Recurring Items | -47.80 | -115.60 | -85.00 | -305.00 | NA |
Diluted Net EPS (GAAP) | -106.20 | -115.60 | -60.00 | -305.00 | -470.00 |
Fiscal Year end for iBio, Inc falls in the month of June .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.05 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.05 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.50 | 5.16 | 4.97 | 6.17 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.50 | -5.11 | -4.97 | -6.17 |
Non-Operating Income | NA | 0.04 | 0.06 | 0.05 | -0.08 |
Interest Expense | NA | 0.03 | 0.03 | 0.02 | 0.04 |
Pretax Income | NA | -4.49 | -5.07 | -4.93 | -6.28 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.49 | -5.07 | -4.93 | -6.28 |
Extras & Discontinued Operations | NA | -3.72 | -0.67 | -1.10 | -1.02 |
Net Income (GAAP) | NA | -8.21 | -5.75 | -6.03 | -7.29 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 1.86 | 1.20 | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | -2.42 | -4.20 | NA | NA |
Diluted Net EPS (GAAP) | NA | -4.42 | -4.80 | 14.20 | -11.00 |